Zomedica Corp. (AMEX:ZOM) finished Thursday with a subtraction of -$0.01 to close at $0.22, a downside of -5.37 percent. An average of 8,684,400 shares of common stock have been traded in the last five days. There was a fall of -$0.0320 in the past week, and it reached a new high 3 times over the past 12 months. The last 20 days have seen an average of 9,457,115 shares traded, while the 50-day average volume stands at 14,495,116.
ZOM stock has decreased by -21.82% in the last month. The company shares reached their 1-month lowest point of $0.2050 on 09/06/22. With the stock rallying to its 52-week high on 02/17/22, shares of the company touched a low of $0.17 and a high of $0.63 in 52 weeks. It has reached a new high 4 times so far this year and lost -29.85% or -$0.0915 in price. In spite of this, the price is down -65.87% from the 52-week high.
Top 5 Cheap Stocks to Own Right Now
While finding safe stocks with the potential for monster gains isn't always easy, we've found a few that could pay out well. In fact, within our report, "Top 5 Cheap Stock to Own Right Now", we have identified five stocks we believe could appreciate the most even if you just have $1,000 to invest.
Sign up here to get your free report now. .
Zomedica Corp. (ZOM) stock’s beta is 0.67. Other valuation ratios to consider include the trailing price-to-sales (P/S) ratio at 17.06, the price-to-book (PB) ratio at 0.80.
The quick ratio of Zomedica Corp. for the three months ended December 30 was 42.40, and the current ratio was 43.50, indicating that the company is able to meet its debt obligations. Further, the company has a long term debt to equity ratio of 0.00 and a total debt to equity ratio of 0.01 for the quarter ending December 30. Its gross profit as reported stood at $3.05 million compared to revenue of $4.13 million.
For investors, determining the potential profitability of the investment also depends on the performance of the company’s management. In the past 12 months, Zomedica Corp.’s return on assets was -6.80%.
In the quarter under review, the net income was up than the previous quarter. The company posted a net income of -$5.27 million in the quarter, while revenues of -$3.94 million were grew 10.63%. The analyst consensus anticipated Zomedica Corp.’s latest quarter earnings to come in at $0 per share, but it turned out to be -$0.01. For the quarter, EBITDA amounted to -$5.04 million. Shareholders own equity worth $979.95 million.
From a technical analysis perspective, let’s take a brief look at Zomedica Corp. (ZOM) price momentum. RSI 9-day as of the close on 22 September was 34.22%, suggesting the stock is Neutral, with historical volatility in this time frame at 59.67%.
As of today, ZOM’s price is $0.2329 -12.96% or -$0.0320 from its 5-day moving average. ZOM is currently trading -24.00% lower than its 20-day SMA and -12.96% lower than its 100-day SMA. However, the stock’s current price level is -14.89% below the SMA50 and -36.82% below the SMA200.
The stochastic %K and %D were 34.11% and 47.71%, respectively, and the average true range (ATR) was 0.0190. With the 14-day stochastic at 17.86% and the average true range at 0.0202, the RSI (14) stands at 37.91%. The stock has reached -0.0122 on the 9-day MACD Oscillator while the 14-day reading was at -0.0092.
The consensus rating for Zomedica Corp. (ZOM) among analysts is Buy. According to current brokerage recommendations, 0 brokerage firms advise that investors sell ZOM, while 0 suggest investors hold. There are 0 analysts who rate the stock as underweight. The stock is rated overweight by 0 analysts, while 1 others rate it as a “buy”.
What is ZOM’s price target for the next 12 months?
Analysts predict a range of price targets between $1.20 and $1.20, with a median target of $1.20. Taking a look at these predictions, the average price target given by analysts for Zomedica Corp. (ZOM) stock is $1.20.